Lytix Biopharma AS (OSL:LYTIX)
Norway flag Norway · Delayed Price · Currency is NOK
8.20
-0.50 (-5.75%)
Aug 5, 2025, 12:36 PM CET

Lytix Biopharma AS Company Description

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States.

Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma.

The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases.

It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of LTX-315 for the treatment of all malignant and pre-malignant dermatological indications.

Lytix Biopharma AS was founded in 2003 and is based in Oslo, Norway.

Lytix Biopharma AS
CountryNorway
Founded2003
IndustryBiotechnology
SectorHealthcare
Employees8
CEOOystein Rekdal

Contact Details

Address:
Sandakerveien 138
Oslo, 0484
Norway
Websitelytixbiopharma.com

Stock Details

Ticker SymbolLYTIX
ExchangeOslo Børs
Fiscal YearJanuary - December
Reporting CurrencyNOK
ISIN NumberNO0010405780
SIC Code2836

Key Executives

NamePosition
Dr. Oystein Rekdal Ph.D.Co-Founder and Chief Executive Officer
Gjest Breistein M.Sc.Chief Financial Officer
Dr. Baldur Sveinbjørnsson Ph.D.Chief Scientific Officer
Dr. Mette Husbyn Ph.D.Chief Technology Officer
Ole Peter NordbyHead of IR and Communication Manager
Jacqueline EarabinoHead of Clinical Operations
Brent Meadows M.B.A.CBO
Dr. Ahmed Bouzidi Ph.D.Senior Vice President of Business Development